Document text
Principal Investigator: Ira J Goldberg
Organization: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Fiscal Year: 2024
Award: $844,212
Funding agency: National Heart Lung and Blood Institute
ABSTRACT
Diabetes markedly increases risk of development of atherosclerotic cardiovascular disease (CVD). Human and
animal data also show that diabetes prevents the normal repair of damaged arteries that occurs upon circulating
LDL cholesterol (LDL-C) reduction. Because of this, patients with diabetes still have greater risk of a
cardiovascular event even after statin reduction of LDL-C than individuals without diabetes. Individuals with
diabetes have greater platelet aggregation, altered white blood cells, and more vascular inflammation,
pathological processes that are improved by LDL-C reduction in unaffected individuals. We hypothesize that by
determining response to LDL-C reduction in T1D, we will identify pathways that can be therapeutically targeted
to optimize vascular repair and prevent CVD events. These data can also be used to determine patient
characteristics that associate with defective response to LDL-C reduction. We propose a clinical study of
response to LDL-C reduction in patients with Type 1 diabetes (T1D). We will recruit the patients from two major
medical centers, NYU Langone and Mount Sinai that serve diverse communities within New York City. Subjects
will be treated for 4 weeks with robust cholesterol-reducing therapies, PCSK9 inhibitors and also either statin
(80 mg atorvastatin) or ezetimibe (10 mg). Each subject will serve as their own control and we will determine
changes in platelets and white blood cells along with circulating inflammatory factors that occur when LDL-C is
markedly reduced. In a subgroup of subjects, changes in vascular inflammation will be determined by
assessment of harvested brachial vein endothelial cells and by uptake of 18F-fluordeoxyglucose into arteries. The
data will be analyzed by an experienced statistician with expertise in diabetes and CVD risk and will identify the
relationship of these changes with HbA1c and glucose variability, and differences between women and men. In
addition, the data in T1D will be compared with similar data assessing response to LDL-C in subjects with Type
2 diabetes and controls to determine abnormalities that differ between these two forms of diabetes.
Terms: <18-FDG><18F- FDG><18FDG><2 Fluoro 2 deoxy D glucose><2-Fluoro-2-deoxyglucose><Abnormal Endothelial Cell><Acceleration><Adrenaline><Adult-Onset Diabetes Mellitus><American Heart Association><Animal Model><Animal Models and Related Studies><Arteries><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Biological Function><Biological Markers><Biological Process><Blood Neutrophil><Blood Platelets><Blood Polymorphonuclear Neutrophil><Blood Vessels><Blood leukocyte><Brittle Diabetes Mellitus><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Carotid Arteries><Characteristics><Cholesterol><Clinic><Clinical Research><Clinical Study><Clinical Trials><Communities><Continuous Glucose Monitor><Cytometry><D-Glucose><Data><Dendritic Cells><Development><Dextrose><Diabetes Mellitus><Endothelial Cells><Epinephrine><Event><Failure><Female><Gene Expression><Glucose><Glycohemoglobin A><Glycosylated hemoglobin A><Harvest><Hb A1><Hb A1a+b><Hb A1c><HbA1><HbA1c><Health Facilities><Health care facility><Healthcare Facility><Heart Vascular><Hemoglobin A(1)><IDDM><Impairment><Individual><Inflammatory><Inflammatory Response><Insulin-Dependent Diabetes Mellitus><Juvenile-Onset Diabetes Mellitus><Ketosis-Prone Diabetes Mellitus><Ketosis-Resistant Diabetes Mellitus><LDL><LDL Cholesterol><LDL Cholesterol Lipoproteins><LDL Lipoproteins><Leukocytes><Leukocytes Reticuloendothelial System><Low Density Lipoprotein Cholesterol><Low-Density Lipoproteins><Macrophage><Marrow Neutrophil><Marrow leukocyte><Marrow platelet><Maturity-Onset Diabetes Mellitus><Measurement><Measures><Medical center><Methods><Mφ><NIDDM><Neutrophilic Granulocyte><Neutrophilic Leukocyte><New York City><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Non-Polyadenylated RNA><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><PBMC><PET><PET Scan><PET imaging><PET/CT><PET/CT scan><PETSCAN><PETT><Pathologic Processes><Pathological Processes><Pathway interactions><Patient Recruitments><Patients><Peripheral Blood Mononuclear Cell><Platelet aggregation><Platelets><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Prediction of Response to Therapy><Process><RNA><RNA Gene Products><Rad.-PET><Research><Research Design><Residual><Residual state><Ribonucleic Acid><Risk><Risk Reduction><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Study Type><Subgroup><Sudden-Onset Diabetes Mellitus><T1 DM><T1 diabetes><T1D><T1DM><T2 DM><T2D><T2DM><T8 Cells><T8 Lymphocytes><Techniques><Testing><Therapeutic Epinephrine><Thrombocytes><Time><Type 1 Diabetes Mellitus><Type 1 diabetes><Type 2 Diabetes Mellitus><Type 2 diabetes><Type I Diabetes Mellitus><Type II Diabetes Mellitus><Type II diabetes><Vascular Endothelial Cell><Veiled Cells><Veins><White Blood Cells><White Cell><Woman><Zetia><abdominal aorta><adult onset diabetes><animal data><atheromatosis><atherosclerotic disease><atherosclerotic vascular disease><atorvastatin><beta-Lipoprotein Cholesterol><beta-Lipoproteins><bio-markers><biologic marker><biomarker><blood glucose regulation><cardiovascular disease risk><cardiovascular disorder><cardiovascular disorder risk><cardiovascular risk><cardiovascular risk factor><care facilities><circulatory system><continuous blood glucose monitor><continuous blood sugar monitor><continuous glucose measurement><continuous sugar monitor><developmental><diabetes><experience><ezetimib><ezetimibe><fluorodeoxyglucose><global gene expression><global transcription profile><glucose control><glucose homeostasis><glucose regulation><glycemic control><hemoglobin A1c><human data><inflammation marker><inflammatory marker><inhibitor><insulin dependent diabetes><insulin dependent type 1><juvenile diabetes><juvenile diabetes mellitus><ketosis prone diabetes><ketosis resistant diabetes><lipitor><mRNA seq><mRNA sequencing><mRNA-seq><mRNAseq><male><maturity onset diabetes><medical college><medical schools><men><model of animal><neutrophil><participant recruitment><pathway><platelet function><positron emission computed tomography><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><predict therapeutic response><predict therapy response><predictive biomarkers><predictive marker><predictive molecular biomarker><prevent><preventing><process improvement><recruit><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><repair><repaired><response><response to therapy><response to treatment><risk-reducing><scRNA-seq><school of medicine><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><study design><therapeutic response><therapeutic target><therapy prediction><therapy response><transcriptome><treatment prediction><treatment response><treatment response prediction><treatment responsiveness><type 2 DM><type I diabetes><type II DM><type one diabetes><type two diabetes><ultrasound><under served community><underserved community><uptake><vascular><vascular inflammation><white blood cell><white blood corpuscle>